ACTRN12622001067763已完成1 期
A Phase 1, first-in-human, 2-part, randomized, double-blind, placebo-controlled, parallel-group, single ascending dose and multiple ascending dose (SAD/MAD) study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ENN0403 in healthy adult subjects.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Capable of giving signed informed consent
- •2. 18 to 55 years old (inclusive)
- •3. BMI of 18 to 30 kg/m2 (inclusive); body weight >50 to <100 kg for male subjects or >45 to <100 kg for female subjects
- •4. Computerized (12-lead) ECG recording without signs of clinically relevant pathology or
- •showing no clinically relevant deviations as judged by the PI
- •5. Test negative for COVID-19
- •6. Test negative for HBsAg, anti-HBc, anti-hepatitis C virus (HCV) antibodies, anti-human immunodeficiency virus (HIV) 1 and 2 antibodies, and tuberculosis.
- •9. Have a negative urine drug screen and a negative alcohol breath test.
- •10. Nonsmoker or occasional smoker and willingness to refrain from smoking during study.
- •11. Ability and willingness to abstain from alcohol during study.
- •13. not pregnant, not breastfeeding; apply contraception methods for child-bearing potential subjects.
排除标准
- •1. History of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease in the opinion of the Investigator within 12 months prior to Screening.
- •2. Any disease or take any medication that affects IP absorption, distribution, metabolism, and excretion.
- •3. Family history of sudden death or of congenital prolongation of the QTc interval or known congenital prolongation of the QTc interval or any clinical condition known to prolong the QTc interval.
- •4. Presence of malignancy including hematological malignancies. Subjects with a history of basal cell or squamous cell carcinoma that has been treated with no evidence of recurrence within 3 years of Screening will be allowed for inclusion, as judged by the Investigator.
- •5. Any current active infections, including localized infections, or any recent history (within 1 week prior to IP administration) of active infections, cough or fever; or a history of recurrent or chronic infections.
- •6. In the 12-lead ECG assessment, QTcF >450 ms for male subjects or >470 ms for female subjects.
- •7. Estimated glomerular filtration rate <90 mL/min (using the Cockcroft-Gault formula) at Screening.
- •8. ALT or aspartate aminotransferase >1.5 × ULN.
- •9. Have received any live vaccines (bacterial or viral) within 12 weeks prior to Screening or intend to receive a live vaccine during the study period or within 30 days after the last dose of the IP.
研究者
相似试验
撤回
不适用
A phase 1, first-in-human, 2-part, randomized, double-blind, placebo controlled, single ascending dose and sequential, open-label, multiple ascending dose study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and participants with autoimmune disease(s)autoimmune hepatitisautoimmune disease(s)1001965410003816AIHNL-OMON51485Parexel Nederland3
已完成
不适用
A First-in-Human study in healthy male volunteers to investigate the safety, tolerability and pharmacokinetics of recombinant human soluble Fc gamma receptor IIb, sFc?RIIb (SM101) administered intravenously as single ascending dosesISRCTN09512688SuppreMol GmbH (Germany)42
已完成
1 期
A study to investigate the safety and concentration in the blood and urine of different dose strengths of OCT461201 in healthy volunteersISRCTN39003837Oxford Cannabinoids Technologies Ltd.32
撤回
不适用
A Phase 1, first-in-human, three-part, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAR443726 in healthy adult participants and in adult participants with moderate-to-severe atopic dermatitis.Eczema10014982Atopic DermatitisNL-OMON51621Sanofi-aventis15
已完成
不适用
A First in Human, Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Total Daily Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Intravenous Infusion of OMN6 in Healthy SubjectsNL-OMON51720Omnix Medical104